-59.1%
CELH vs MRNA
+34.8%
-93.9%
-77.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +2.2% | +5.4% | -3.2% | +1.8% |
| 7D | -11.2% | -1.1% | -10.1% | -11.1% |
| 30D | -1.4% | +126.1% | -127.6% | -13.1% |
| 3M | -4.2% | +190.0% | -194.2% | -18.5% |
| 6M | -40.5% | +157.2% | -197.7% | -48.8% |
| YTD | -40.5% | +388.2% | -428.7% | -53.9% |
| 1Y | -53.0% | +467.0% | -520.0% | -64.8% |
| 3Y | -59.1% | +36.1% | -95.1% | -62.4% |
| All | -59.1% | +34.8% | -93.9% | -62.4% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling